Q-omics provides the consensus-scored TMPRSS15 profile across patient tissues and cancer cell-line models. TMPRSS15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMPRSS15 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, TMPRSS15 RNA expression shows 7,414 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where TMPRSS15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPRSS15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPRSS15 survival associations across molecular data types. TMPRSS15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPRSS15 RNA expression–survival associations across cancer types. High TMPRSS15 expression shows unfavorable associations in KIRP, LGG and UVM, but favorable associations in LUSC, DLBC and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for TMPRSS15 RNA expression.
This table summarizes TMPRSS15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TMPRSS15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPRSS15 shows lower tumor expression in KICH and KIRP and higher tumor expression in LUSC, HNSC, LIHC and LUAD. The KICH box plot shows higher TMPRSS15 RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .003).
This table shows molecular features associated with TMPRSS15 in patient tissues and cancer cell lines. In patient samples, TMPRSS15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMPRSS15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
